NTX-748

1 paper3 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Funders: National Institute on Aging and 1 more

Animals1

Outcomes

Long-term potentiation

upin mice1

1 study

NTX-748 improves long-term potentiation in mice.
“elevating systemic and brain NAD+ levels, improving long-term potentiation, and enhancing multiple domains of cognition in aged mice”
Animals
CD38 Inhibition Ameliorates Age-Related CognitiveDecline via a Choroid Plexus-Cerebrospinal Fluid-Hippocampus Axis
Research square6 Jan 2026Preprint

NAD+

upin mice1

1 study

NTX-748 increases NAD+ in mice.
“elevating systemic and brain NAD+ levels, improving long-term potentiation, and enhancing multiple domains of cognition in aged mice”
Animals
CD38 Inhibition Ameliorates Age-Related CognitiveDecline via a Choroid Plexus-Cerebrospinal Fluid-Hippocampus Axis
Research square6 Jan 2026Preprint

Latest

1 in 12 months

Research Square16 Jan

CD38 Inhibition Ameliorates Age-Related CognitiveDecline via a Choroid Plexus-Cerebrospinal Fluid-Hippocampus Axis

Preprint: experiments in miceInterventions

Paper